News

No significant difference in efficacy outcomes were shown with bintrafusp alfa vs pembrolizumab in patients with PD-L1-high, advanced non–small cell lung cancer. However, further investigation may offer more information about the benefit of this drug class.

Alectinib is the first and only ALK inhibitor to demonstrate a reduction in disease recurrence among patients with early-stage ALK-positive non–small cell lung cancer, based on data from the phase 3 ALINA study.

In season 4, episode 13 of Targeted Talks, Benny Weskler, MBA, MD, FACS, FACCP, discusses neoadjuvant therapy for patients with non–small cell lung cancer.

In an interview with Targeted Oncology, Ruchi Garg, MD, discussed the evolution of the treatment landscape for patients with endometrial cancer and what trials to watch out for in the future.

Following positive results from cohorts 1 and 2 of the SECuRE trial, dosing of 64Cu/67Cu SAR-bisPSMA has begun in patients with metastatic castration-resistant prostate cancer in cohort 3.

Fam-trastuzumab deruxtecan-nxki was granted 2 breakthrough therapy designations by the FDA for its potential to fill a treatment gap for HER2-expressing tumors.

RefleXion X1 is now being used at City of Hope Comprehensive Cancer Center.

In an interview Targeted Oncology, Christina Fotopoulou, MD, PhD, discussed the background and results of 3 studies for patients with ovarian cancer.

Amid the ongoing chemotherapy drug shortage in the United States, experts like Nathan Bahary, MD, and Anne LaCasce, MD, MMSc, push for the passing of legislation, yet keep their patients their top priority.

The phase 1/2 BEXMAB study is investigating the combination of bexmarilimab with standard of care in patients with hematologic malignancies.

A retrospective study found no additional benefit for patients with non–small cell lung cancer who continued immunotherapy beyond 2 years.

Promising overall survival findings from cohort 1 of the THOR study evaluating erdafitinib in locally advanced or metastatic urothelial cancer have pushed the agent’s developer to submit an sNDA seeking its full approval.

Study results suggest that patients with myelodysplastic syndrome have the potential to benefit from HCT regardless of their genetic mutations.

The FDA has added to the existing approval of luspatercept-aamt for the treatment of patients with anemia and lower-risk myelodysplatic syndrome.

Combination therapies utilizing ofatumumab could improve outcomes for patients with chronic lymphocytic leukemia, according to an analysis published in the Annals of Hematology.

Chad Tang, MD, discusses ongoing challenges for the treatment of patients with oligometastatic prostate cancer.

Treatment with an investigational mitochondrial inhibitor and bevacizumab has started in a phase 1b clinical trial of patients with previously-treated metastatic colorectal cancer.

The primary end point was not met in the phase 3 ENGOT-ov50 / GOG-3029 / INNOVATE-3 clinical trial of tumor treating fields therapy plus paclitaxel in patients with platinum-resistant ovarian cancer.

The phase 2 SWOG S1801 trial showed a 42% reduction in 2-year event-free survival for neoadjuvant-adjuvant vs adjuvant-only pembrolizumab for resectable stage IIIB-D/IV melanoma.

Ivonescimab is being investigated in phase 3 clinical trial against the combination of tislelizumab and chemotherapy.

A single-arm trial induced high event-free and overall survival with the addition of durvalumab to standard of care before radical surgery in patients with muscle-invasive urothelial carcinoma.

A coprimary end point in the phase 3 LEAP-010 study will not be met.

Based on positive phase 3 PAPILLON results, an application for a new approval for amivantamab has been filed with the FDA.

Immune checkpoint inhibitors are approved for dMMR/MSI-H gastrointestinal cancer treatment; however, approximately half of patients with dMMR/MSI-H gastrointestinal cancer exhibit primary resistance to them.

Frontline treatment with AK112, a first-in-class humanized IgG1 bispecific antibody, plus chemotherapy demonstrated promising overall responses across 3 cohorts in a phase 2 trial.

Experts believe VAL-083 has the potential to change the way oncologists treat glioblastoma in the future.

Novel agents are now under development for newly druggable targets in patients with solid tumors.

FDA notices NXC-201 for its potential offer a novel mechanism to treat patients with multiple myeloma.

Patients treated with VT1021 for recurrent glioblastoma were found to have immune markers associated with response to treatment in a phase 1/2 study.